Bacteria

Onkos Surgical Announces First FDA De Novo Approval of an Antibacterial Coating for Tumor and Revision Orthopaedic Implants

Retrieved on: 
Monday, April 8, 2024
Failure, De novo, Health, Prevalence, Infection, Arthroplasty, Patient, Trauma, Mortality, Bacteria, Osteoporosis, Food and Drug Administration, Neoplasm, Amputation, FDA, Onko, Pharmaceutical industry

PARSIPPANY, N.J., April 8, 2024 /PRNewswire/ -- Onkos Surgical, an orthopaedic company founded to address the complex clinical challenges associated with bone loss due to tumor, trauma, and revision surgery, announced that the U.S. Food & Drug Administration (FDA) granted the company a De Novo approval for its novel antibacterial coated implants. Bacterial contamination of a permanent implant may have devastating effects, particularly in orthopedic oncology and revision arthroplasty applications where the patient population is highly vulnerable.

Key Points: 
  • PARSIPPANY, N.J., April 8, 2024 /PRNewswire/ -- Onkos Surgical, an orthopaedic company founded to address the complex clinical challenges associated with bone loss due to tumor, trauma, and revision surgery, announced that the U.S. Food & Drug Administration (FDA) granted the company a De Novo approval for its novel antibacterial coated implants.
  • Bacterial contamination of a permanent implant may have devastating effects, particularly in orthopedic oncology and revision arthroplasty applications where the patient population is highly vulnerable.
  • "Implant contamination is a growing concern to the orthopaedic surgical community," said Steven Gitelis, MD, Onkos Surgical Chief Medical Officer, Rush Medical College, Endowed Professor of Orthopaedic Oncology and Director, Musculoskeletal Oncology at Rush Cancer Center.
  • The Onkos technology is a significant innovation and another option to help reduce local bacterial load on the implant."

LANDSEA HOMES LAUNCHES HIGH PERFORMANCE HOME PROGRAM IN COLORADO; CELEBRATES GRAND OPENINGS FOR TWO NEW COMMUNITIES

Retrieved on: 
Monday, April 8, 2024
Highlands Preserve, Apple, REME, Partnership, Geek Squad, Carbon footprint, Acquisition, Bacteria, Virus, Dander, Dust, House, Thermostat, Pollen, Sustainability, Lighting, LED, Health

*

Key Points: 
  • *
    The company's notable homes merge design, technology, and sustainability to promote energy savings and a healthy lifestyle.
  • Landsea Homes entered the Colorado housing market last October via the acquisition of Richfield Homes.
  • All of Landsea Homes' High Performance Homes are supported by a partnership with Apple®, the homes utilize the Apple HomeKit™ environment to operate all home automation features from one mobile application.
  • For more information about Landsea Homes' High Performance Home program, visit https://landseahomes.com/hph .

Environmental Remediation Market to Reach $218.8 billion, Globally, by 2032 at 7.1% CAGR: Allied Market Research

Retrieved on: 
Monday, April 8, 2024
Soil, International Energy Agency, Pesticide, Health, Microalgae, Habitat, Organization, PDF, Urbanization, Face, Agriculture, Water pollution, Natural Resources, Public, Fungus, Bacteria, Transport, Groundwater, Plant, Atmosphere, Water, Ecosystem, IEA, Table, Environmental remediation

PORTLAND, Ore., April 8, 2024 /PRNewswire/ -- Allied Market Research published a report, titled, "Environmental Remediation Market by Site-Type (Public and Private), Medium (Soil and Groundwater), Technology (Air Sparging, Soil Washing, Chemical Treatment, Bioremediation, Electrokinetic Remediation, Excavation, and Permeable Reactive Barriers), and Application (Mining & Forestry, Oil & Gas, Agriculture, Automotive, Landfills and Waste Disposal Sites, Manufacturing, Industrial, and Chemical Production/Processing, Construction and Land Development, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032". According to the report, the "environmental remediation market" was valued at $110.7 billion in 2022, and is estimated to reach $218.8 billion by 2032, growing at a CAGR of 7.1% from 2023 to 2032.

Key Points: 
  • The Russia-Ukraine war had significant implications on the environmental remediation market, affecting both the demand for remediation services and the resources available for environmental cleanup efforts.
  • As a result, there is an increased need for environmental remediation services to address these pollution incidents and mitigate their impacts.
  • Geopolitical tensions and economic sanctions stemming from the Russia-Ukraine war impact international cooperation and investment in environmental remediation initiatives.
  • Collaboration between countries and organizations on transboundary pollution issues and environmental cleanup projects are expected to be strained, leading to delays or disruptions in remediation efforts.

Environmental Remediation Market to Reach $218.8 billion, Globally, by 2032 at 7.1% CAGR: Allied Market Research

Retrieved on: 
Monday, April 8, 2024
Soil, International Energy Agency, Pesticide, Health, Microalgae, Habitat, Organization, PDF, Urbanization, Face, Agriculture, Water pollution, Natural Resources, Public, Fungus, Bacteria, Transport, Groundwater, Plant, Atmosphere, Water, Ecosystem, IEA, Table, Environmental remediation

PORTLAND, Ore., April 8, 2024 /PRNewswire/ -- Allied Market Research published a report, titled, "Environmental Remediation Market by Site-Type (Public and Private), Medium (Soil and Groundwater), Technology (Air Sparging, Soil Washing, Chemical Treatment, Bioremediation, Electrokinetic Remediation, Excavation, and Permeable Reactive Barriers), and Application (Mining & Forestry, Oil & Gas, Agriculture, Automotive, Landfills and Waste Disposal Sites, Manufacturing, Industrial, and Chemical Production/Processing, Construction and Land Development, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032". According to the report, the "environmental remediation market" was valued at $110.7 billion in 2022, and is estimated to reach $218.8 billion by 2032, growing at a CAGR of 7.1% from 2023 to 2032.

Key Points: 
  • The Russia-Ukraine war had significant implications on the environmental remediation market, affecting both the demand for remediation services and the resources available for environmental cleanup efforts.
  • As a result, there is an increased need for environmental remediation services to address these pollution incidents and mitigate their impacts.
  • Geopolitical tensions and economic sanctions stemming from the Russia-Ukraine war impact international cooperation and investment in environmental remediation initiatives.
  • Collaboration between countries and organizations on transboundary pollution issues and environmental cleanup projects are expected to be strained, leading to delays or disruptions in remediation efforts.

Philips GoPure GP5212 Automotive Air Purifier Removes up to 90% of Airborne Pollen Inside Vehicles

Retrieved on: 
Friday, April 5, 2024
Filter (signal processing), Gas, HESA, Bacteria, Virus, SO2, Particulates, Dust, Pollen, Multimedia, Air pollution, NO2, SUV, HEPA, Allergen

FARMINGTON HILLS, Mich., April 5, 2024 /PRNewswire/ -- Lumileds, a leading lighting solutions company, offers the Philips GoPure GP5212 Automotive Air Purifier for those who suffer from seasonal allergies. Powerful, compact, and simple to use, GoPure GP5212 effectively filters out airborne allergens including pollen and mold that can pass through the cabin filters typically found in vehicles. Standard cabin air filters typically trap particulates of 5-100 microns. The Philips GoPure GP5212 can filter particles as small as .015 microns, including allergens, viruses, and bacteria, as well as toxic gases. The advanced filtering of the GoPure GP5212 helps trap pollen, keeping it out of the eyes and airways of vehicle occupants.

Key Points: 
  • The Philips GoPure GP5212 can filter particles as small as .015 microns, including allergens, viruses, and bacteria, as well as toxic gases.
  • The advanced filtering of the GoPure GP5212 helps trap pollen, keeping it out of the eyes and airways of vehicle occupants.
  • Phillips GoPure GP5212 car air purifier meets a growing demand for clean air solutions.
  • "The new Phillips GoPure GP5212 car air purifier meets a growing demand for clean air solutions," noted Aubry Baugh, Lumileds Sr.

Orphan designation: Lactobacillus plantarum Treatment of amyotrophic lateral sclerosis, 16/12/2019 Positive

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Civil service commission, Diagnosis, DSM-IV codes, Brain, Disease, ALS, Paralysis, Nervous system, Patient, Committee, Knowledge, Lactiplantibacillus plantarum, Regulation, Bacteria, EMA, IRIS, Death, Respiratory failure, Woman, Saliva, European, COMP, Spinal cord, Safety, European Commission, MDC, Riluzole, Marketing, Hand, Medicine, Pharmaceutical industry

Orphan designation: Lactobacillus plantarum Treatment of amyotrophic lateral sclerosis, 16/12/2019 Positive

Key Points: 


Orphan designation: Lactobacillus plantarum Treatment of amyotrophic lateral sclerosis, 16/12/2019 Positive

Orphan designation: Azithromycin dihydrate Prevention of bronchopulmonary dysplasia, 14/01/2022 Positive

Retrieved on: 
Tuesday, April 9, 2024
Community, Diagnosis, Civil service commission, Bronchopulmonary dysplasia, Ureaplasma urealyticum infection, BPD, Prevalence, Protein, Disease, Infection, Clinical, Inflammation, Patient, Committee, Bacteria, EMA, IRIS, Update, Agency, European, COMP, European Commission, Marketing, Medicine, Pharmaceutical industry

Overview

Key Points: 
  • Overview
    This medicine was designated as an orphan medicine for the prevention of bronchopulmonary dysplasia in the European Union on 14 January 2022.
  • All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
  • The full list of orphan designations is available in the Community register of orphan medicinal products for human use.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Positive

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Absorption, Lower respiratory tract infection, Exercise, Cell, Infection, DSM-IV codes, Inflammation, Patient, Committee, Cystic fibrosis, Knowledge, Digestion, Regulation, Bacteria, Food, EMA, IRIS, Anti-inflammatory, Mucus, CB2, European, COMP, Pancreas, Sponsor, Ivacaftor, European Commission, Safety, CFTR, Marketing, Medicine, Pharmaceutical industry

Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Positive

Key Points: 


Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Positive

To Bolster Global Efforts in Combating Antibiotic-Resistant Bacteria KFSH&RC Scientists Discover New Bacteria Species: Riyadhensis

Retrieved on: 
Monday, March 25, 2024
WGS, Health, Disease, Education, Patient, Research, Hospital, Bacteria, Pseudomonas aeruginosa, RC, KFSH, Infection, Intensive care medicine, Newsweek, ICU, Vaccine

RIYADH, Saudi Arabia, March 25, 2024 (GLOBE NEWSWIRE) -- In a ground-breaking development, scientists at King Faisal Specialist Hospital and Research Centre (KFSH&RC) have identified a new species of bacteria, referred to as "Stenotrophomonas Riyadhensis" through the application of whole-genome sequencing (WGS) technology. This discovery signifies a major advancement in understanding how bacteria interact with existing drugs, paving the way for innovative therapeutic strategies. Such efforts are essential in the global fight against antibiotic-resistant bacteria, highlighting KFSH&RC’s advanced research capabilities and its leading role in fostering scientific discoveries and enhancing patient care.

Key Points: 
  • This discovery signifies a major advancement in understanding how bacteria interact with existing drugs, paving the way for innovative therapeutic strategies.
  • Such efforts are essential in the global fight against antibiotic-resistant bacteria, highlighting KFSH&RC’s advanced research capabilities and its leading role in fostering scientific discoveries and enhancing patient care.
  • This represents substantial progress in combating antibiotic resistance, developing pharmaceuticals, and preventing the spread of diseases.
  • Furthermore, this approach lays the groundwork for scientific collaboration at all levels, enhancing global efforts to combat antibiotic resistance.

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Monday, March 25, 2024
Toxicity, B cell, CD8, Research, Cancer research, AACR, Chemokine, Therapy, Cytokine, Immune system, Poster, Viral, Decoy, Bacteria, Vaccine

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces that Dr. Michael Newman, Founder and Chief Scientific Officer of Indaptus, will present a poster at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego on Wednesday morning, April 10th. An abstract of the data to be presented has been published online in the AACR Journal, Cancer Research. The data confirm and significantly extend the proposed mechanism of action of the Company’s proprietary platform technology of attenuated and killed, non-pathogenic bacteria containing multiple immune receptor agonists for pulsed anti-tumor immunotherapy.

Key Points: 
  • An abstract of the data to be presented has been published online in the AACR Journal, Cancer Research.
  • The data confirm and significantly extend the proposed mechanism of action of the Company’s proprietary platform technology of attenuated and killed, non-pathogenic bacteria containing multiple immune receptor agonists for pulsed anti-tumor immunotherapy.
  • The activity was associated with induction of human tumor cell killing by Decoy bacteria in the presence of immune cells.
  • Potentially unacceptable toxicity from this breadth of immune activation is avoided by using systemically administered killed bacteria as a delivery vehicle.